|Bid||33.36 x 2200|
|Ask||33.37 x 1600|
|Day's Range||33.24 - 33.48|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.01|
|Dividend & Yield||1.28 (3.82%)|
|1y Target Est||N/A|
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.
In 2016, Pfizer’s (PFE) Xeljanz reported revenues of ~$927 million, which reflected a ~77% growth YoY (year-over-year).
Twenty-two analysts covered Merck in July 2017. Four analysts recommended a “strong buy” while ten analysts recommended a “buy.”